Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL

Paolo Ghia • 1 Dec 2016
ASH 2016
Chronic Lymphocytic Leukemia Chlorambucil Ibrutinib
RESONATE-2

Paolo Ghia, MD, PhD of Università Vita-Salute San Raffaele, Milan, Italy, discusses the re-analysis of the RESONATE-2 trial comparing chlorambucil vs ibrutinib as first-line treatment for elderly chronic lymphocytic leukemia (CLL) patients with co-morbidities (NCT01722487). The update shows the data is still consistent with the original results; ibrutinib shows high efficacy and this translates in overall survival (OS). Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals